Insulin Sensitivity After Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-45
SponsorUniversity of Copenhagen
About this trial
Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and/or treatment-induced molecular changes in skeletal muscle from BC survivors .
Eligibility criteria
Qualifiers
Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination
BMI: 25-30
Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects
Disqualifiers
Known postmenopause occurred at the time of diagnosis of breast cancer
Alcohol intake of> 7 items / week
Smoker
Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof.
Trial design
Treatments tested in this trial
- Insulin
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov